Alcon Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Alcon heeft een totaal eigen vermogen van $20.9B en een totale schuld van $4.7B, wat de schuld-eigenvermogensverhouding op 22.4% brengt. De totale activa en totale passiva bedragen respectievelijk $29.7B en $8.8B. De EBIT Alcon is $1.2B waardoor de rentedekking 8.2 is. Het heeft contanten en kortetermijnbeleggingen van $1.4B.

Belangrijke informatie

22.4%

Verhouding schuld/eigen vermogen

US$4.69b

Schuld

Rente dekkingsratio	8.2x
Contant	US$1.37b
Aandelen	US$20.94b
Totaal verplichtingen	US$8.78b
Totaal activa	US$29.72b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Alcon to acquire U.S. commercialization rights to ophthalmic eye drops Simbrinza from Novartis

Apr 28

Alcon: Global Leader In An Attractive End-Market

Dec 16

Alcon Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 11

Alcon Q3 2020 Earnings Preview

Nov 09

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $6.0B ) ALC } overtreffen de korte termijn passiva ( $2.3B ).

Langlopende schulden: De kortetermijnactiva van ALC ( $6.0B ) dekken de langetermijnschulden ( $6.4B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 15.8% ) ALC wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van ALC is de afgelopen 5 jaar gestegen van 18.1% naar 22.4%.

Schuldendekking: De schuld van ALC wordt goed gedekt door de operationele kasstroom ( 39.4% ).

Rentedekking: De rentebetalingen op de schuld van ALC worden goed gedekt door EBIT ( 8.2 x dekking).

Alcon Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Alcon Q2: Positive News From Unity VCS/CS And AR-15512

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Alcon Inc. Maintains Earnings Guidance for the Year 2024

Now 21% undervalued

Alcon: Trading At An Undeserved Premium Valuation

Alcon's Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance

First quarter 2024 earnings: EPS exceeds analyst expectations

Alcon Q1: Robust Product Pipeline Drives Future Growth (Rating Upgrade)

Upcoming dividend of CHF0.16 per share

Alcon Inc. Approves Gross Dividend

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and Its Hydrus Microstent for Microinvasive Glaucoma Surgery

Alcon Announces Management Changes

Alcon Inc. Launches Clareon Presbyopia Correcting IOLs in India

Dividend of CHF0.16 announced

Alcon Inc. Proposes Dividend for the Year 2023

Full year 2023 earnings: EPS exceeds analyst expectations

Alcon Announces Positive Topline Results from Phase 3 Comet Trials of AR-15512, A Novel Topical Drug Candidate for Dry Eye

Alcon Inc., Annual General Meeting, May 08, 2024

Alcon Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Alcon Inc. Showcases Cloud-Based Planning and World-Class Digital Technologies During AAO 2023

Alcon Launches Total30 Multifocal Contact Lenses for Patients with Presbyopia

Alcon: Buy An Eyecare Leader With $2 Billion In Quarterly Sales

Alcon Inc. Raises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.34 (vs US$0.30 in 2Q 2022)

Alcon: Lackluster Growth Given Its Valuation

Alcon: The Steady Force Of 'Boring'

Price target increased by 8.4% to US$85.32

Price target increased by 7.9% to US$84.07

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Provides Earnings Guidance for the Year 2023

Alcon Announces Results from a New Study Presented at the American Society of Cataract and Refractive Surgery Annual Meeting

Alcon Inc. Approves Dividend

Upcoming dividend of CHF0.14 per share at 0.3% yield

Full year 2022 earnings: EPS misses analyst expectations

Alcon Inc. Announces Settlement of Litigation Related to Femtosecond Laser Assisted Cataract Surgery Devices

Alcon reached $199M settlement with J&J Surgical Vision

Alcon Launches New Total Toric Lenses for Astigmatic Patients

Alcon: Case Of Growth Destructive To Value, Reiterate Hold At 24x Earnings

Alcon Inc., Annual General Meeting, May 05, 2023

Alcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for Astigmatism

Alcon a buy at Mizuho on 'eyecare dominance'

Alcon Inc. Updates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Insufficient new directors

Alcon Inc. Revises Revenue Guidance for 2022

Alcon Q3 2022 Earnings Preview

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon: Looking To Break Downtrend Before Entry

Alcon Inc. (SWX:ALC) entered into a definitive merger agreement to acquire Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI) for approximately $770 million.

Alcon downgraded to hold at Societe Generale on macro headwinds

Second quarter 2022 earnings: EPS exceeds analyst expectations

Alcon Inc. Revises Revenue Guidance for 2022

Alcon: Revisiting The Investment Thesis

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

Alcon Inc. Reaffirms Earnings Guidance for the Fiscal 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alcon Inc. Declares Dividend for 2021

Insufficient new directors

Alcon Announces Key Data to Be Presented at This Year’s American Society of Cataract and Refractive Surgery Meeting on its SMART Solutions for Cataract Surgery

Upcoming dividend of CHF0.13 per share

The Recent Pullback Makes Alcon More Attractive

Alcon Inc. Announces Launch of Clareon Portfolio in the U.S

Full year 2021 earnings: EPS exceeds analyst expectations

Alcon Inc. Proposes Dividend

Alcon Inc. Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe

Alcon: Good Quarterly Results, But It Is Still Expensive

Alcon Continues Its Successful Rollout of Precision1 Daily Disposable Contact Lenses, Now Available in Key Markets Throughout Latin America, Asia & Europe

Third quarter 2021 earnings released: EPS US$0.004 (vs US$0.30 loss in 3Q 2020)

Looking At Alcon Through A Different Lens

President of Global Business & Innovation Michael Onuscheck has left the company

Price target increased to US$80.88

Second quarter 2021 earnings released: EPS US$0.31 (vs US$0.86 loss in 2Q 2020)

Alcon to Launch TOTAL30 as the First-and-Only Monthly Replacement, Water Gradient Contact Lens

First quarter 2021 earnings released: EPS US$0.17 (vs US$0.12 loss in 1Q 2020)